Sequential extraction of wheat seed proteins.

A. Görg,O. Drews,W. Weiss

DOI: https://doi.org/10.1101/pdb.prot4228

2006-06-01

Cold Spring Harbor Protocols

Abstract:

What problem does this paper attempt to address?

Randomized and Double-Blind Controlled Clinical Trial of Tilidine Hydrochloride Oral Solution for Analgesia

SUN Li,LI Xiao-xiao,LIANG Jun-cheng,ZHU Tian-yue,XIE Qi-wei,LIU Duan-qi,XIE Guang-ru,XU Guo-zhu,DENG Yan-ping

DOI: https://doi.org/10.3969/j.issn.1001-6821.2013.01.002

2013-01-01

Abstract:Objective To evaluate the efficacy and safety of tilidine hydrochloride oral solution for analgesia.Methods A multicenter,randomized,double blind,parallel group controlled study was performed with tilidine as the test drug and morphine hydrochloride tablets as control for the treatment of moderate and severe pain.One hundres fourty-four postoperative pain patients were received single treatment with tilidine(single oral tilidine and morphine placebo,n=73) or morphine(single oral morphine and tilidine placebo,n=71).Fifty eight cancer patients were received 5 days treatment with tilidine or morphine.Pain intensity difference(PID) was evaluated as the primary analgesic effect criteria.Results There was no significant difference in PID between the test group and the control one both in the controlled trail of postoperative pain and that of chronic cancer pain.The most common adverse reactions of tilidine were dizziness,nausea and vomiting et al.Conclusion The analgesic effect and adverse effects of tilidine were similar to that of morphine,which indicated tilidine was an effective and safe analgesic for postoperative pain and chronic cancer pain that were moderate and severe pain.
Maternal diabetes mellitus is associated with altered deposition of fibrin-type fibrinoid at the villous surface in term placentae.

Terry M. Mayhew,C. Sampson

DOI: https://doi.org/10.1053/PLAC.2002.0953

IF: 3.287

2003-05-01

Placenta

Abstract:Placentae from control and diabetic patients were used to test three null hypothesis: (1) there are no significant group differences in the volumes of villous syncytiotrophoblast compartments or intervillous fibrin-type fibrinoid, (2) perivillous fibrin-type fibrinoid is deposited randomly at the surface of trophoblast, and (3) amounts and deposition patterns of perivillous fibrin-type fibrinoid do not vary between groups. Term placentae were collected from non-diabetic subjects and five groups of diabetic women classified according to duration, severity and insulin dependence. Tissue specimens and sections were obtained by uniform random sampling. Volumes and surface areas of fibrin-type fibrinoid and trophoblast compartments (thin, syncytial knot, syncytial bridge and denuded regions) were estimated stereologically and compared using variance, chi-squared and contingency table analyses. As to null hypothesis (1), no group differences in volumes of trophoblast compartments were found but volumes of intervillous fibrin-type fibrinoid were greater in the non-insulin-dependent diabetic group. As to null hypothesis (2), regardless of group, fibrin-type fibrinoid was deposited preferentially at sites of denudation in every placenta examined. As to null hypothesis (3), villous surface areas occupied by perivillous fibrin-type fibrinoid were greater in type 1 (insulin-dependent) diabetics with complications (diabetic nephropathy or retinopathy). The surfaces of trophoblast occupied by fibrin-type fibrinoid were also notably larger in non-insulin-dependent diabetics and type 1 diabetics with complications. Except for the surface of denudation sites (which also increased in diabetes), there were no differences in the surfaces of trophoblast regions. These results confirm that the haemostatic steady state is perturbed in the diabetic placenta, that perivillous fibrin-type fibrinoid is deposited preferentially at sites of epithelial loss/damage, and that some diabetic groups are affected differentially.
A novel opioid/pramipexole combination treatment for the management of acute pain: a pilot study

Cara Girardi,Joseph Duronio,Ryan Patton,Kevin O'Brien,Stefan Clemens,Kori L Brewer

DOI: https://doi.org/10.3389/fpain.2024.1422298

2024-09-24

Abstract:Purpose: Despite their dangerous side effects, opioid drugs remain a standard of care for moderate to severe pain with few alternatives. Strategies to maintain the analgesic effects of opioids while minimizing the associated risks are needed. Pre-clinical studies have shown using a dopamine 3 receptor (D3R) agonist as an adjuvant to morphine provides superior analgesia against painful stimuli compared to morphine alone. Our objective was to test if adjunct treatment with a D3R agonist can lead to a reduction in opioid use while maintaining effective analgesia. Patients and methods: This study was set up as a double-blinded, placebo-controlled randomized trial. Enrollment included acute renal colic patients presenting to the emergency department, from which patients were randomized to either the "control" or "study arm". The control group received standard treatment of care (morphine, 0.1 mg/kg; i.v.) and an oral placebo pill. The experimental group received half-dosed morphine and oral pramipexole pill (0.25 mg). Pain measurements including a numerical pain scale and visual analog scale were collected from enrollees at baseline and every subsequent 15 min. Results: A total of 19 patients completed the study, 10 in the experimental arm and 9 in the control arm. During the study period, effective analgesia (50% decrease from baseline) was achieved in 80% of patients in the experimental arm vs. 33.3% in the control arm. Conclusion: Our pilot clinical trial demonstrated that D3R recruitment can serve as an effective adjuvant to low-dose morphine for control of renal colic pain and potentially other acute pain conditions. Clinical trial registration: ClinicalTrials.gov, identifier, (NCT04160520).
Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial

Alexander Hincker,Matthew Reschke,Yehuda Ginosar,Leonid Kagan,Evan D. Kharasch,Anna Siemiątkowska,Celine Park,Kristopher Bakos,Arbi Ben‐Abdallah,Simon Haroutounian

DOI: https://doi.org/10.1111/bcp.16178

2024-07-25

British Journal of Clinical Pharmacology

Abstract:Aims Epidural opioids can provide effective analgesia for acute postoperative pain. Due to its unique physicochemical properties and long systemic elimination half‐life, epidural methadone may provide lasting analgesia with minimal adverse effects; however, human studies are lacking. The aim of the study was to test the hypothesis that epidural methadone would exhibit greater segmental analgesia (analgesia at the dermatome of injection vs. distant dermatomes) than epidural morphine. Methods In a prospective, randomized, double‐blinded, crossover study, thirteen healthy volunteers received a 4‐mg epidural bolus of methadone or morphine at L3–L4 and underwent repeated assessment of dermatomal heat pain tolerance and pressure pain threshold at lumbar (L3) and trigeminal (V2) dermatomes, pupil diameter, respiratory parameters and venous opioid concentration for 24 h. The primary outcome was selective (lumbar vs. trigeminal) segmental analgesia for heat pain, as a marker of a spinal analgesic mechanism. Results The degree of segmental analgesia to heat pain tolerance was not different between morphine and methadone (P = .09), although morphine (P = .0009) but not methadone (P = .81) produced significant analgesia to heat pain at the lumbar vs. trigeminal dermatome over 0–12 h. Morphine overall provided longer lasting analgesia to heat pain vs. methadone (24 vs. 2 h, respectively). Morphine elicited greater systemic effects, including miosis (P = .009) and opioid‐related adverse effects (P = .002). Conclusions These results suggest that, with equal epidural doses, both methadone and morphine produced analgesia and methadone did not produce greater segmental effects than morphine. Epidural methadone provided a more favourable adverse effect profile.

pharmacology & pharmacy
Assessment of suicidal behavior in the emergency department.

S. Targum,F. Friedman,M. Pacheco

2014-09-01

Abstract:194 INTRODUCTION Dr. Targum: Hospital emergency departments see a lot of people who are seriously thinking about suicide or have made suicide attempts. In fact, emergency departments (ED) in the United States treat over 500,000 people annually for suicide-related issues. Within many healthcare systems, the ED has become a critical thoroughfare (the default option) for acute and chronically suicidal patients. Mills et al found that the ED had the second highest number of reported completed suicides and attempts within the Veterans Affairs (VA) healthcare system and was second only to inpatient psychiatric units. Suicide attempts leading to ED visits are not restricted to any age group, ethnicity, or socio-economic status and are not always associated with psychiatric comorbidity like depression, conduct disorder, or substance abuse. Suicide attempts leading to ED visits occur in adolescents as well as the elderly, may be impulsive or deliberate, may follow alcohol intoxication, and vary widely in the actual intent to die. The obvious high risk of a repeat suicide attempt generates an urgency to make an accurate assessment and create a safe, yet plausible treatment plan. ED physicians need to quickly assess the potential lethality of suicidal patients and determine whether to retain them (hospital admission) or discharge them. The majority of suicide attempt patients seen in the ED are discharged without hospitalization after medical stabilization and psychosocial evaluation. Yet, these patients still have a high risk for repeated attempts. Up to 25 percent of these suicide attempters return to the ED after another attempt, and 5 to 10 percent eventually die by suicide. Given this context, it is intriguing that hospitalization rates following suicide attempt-related ED visits actually decreased from 49 percent to 32 percent during the same time period (1992–2001) that ED visits for suicide attempts had increased by 47 percent. Clearly, the ED is a vital setting for suicide prevention and may be the only access to healthcare available for some patients. Of course, the busy ED has to deal with cardiac arrests, gun shot wounds, sick babies, and every other conceivable medical emergency at the same time that they assess a suicidal patient. For this column, I discuss the assessment of suicidal patients with two physicians who work at the very busy ED at Tufts Medical Center in downtown Boston, Massachusetts. Their views go beyond the theoretical and reflect the experience and wisdom of physicians who work on the front line of healthcare. Dr. Frank Friedman is an Assistant Professor of Emergency Medicine at Tufts University School of Medicine and the Director of Prehospital Care and Emergency Preparedness at Tufts Medical Center. Dr. Manuel N. Pacheco is an Assistant Professor of Psychiatry at Tufts Research to Practice
The use of a battery of pain models to detect analgesic properties of compounds: a two-part four-way crossover study

Pieter Okkerse,Guido van Amerongen,Marieke L de Kam,Jasper Stevens,Richard P Butt,Rachel Gurrell,Albert Dahan,Joop M van Gerven,Justin L Hay,Geert Jan Groeneveld

DOI: https://doi.org/10.1111/bcp.13183

Abstract:Aim: The aim was to investigate the ability of a battery of pain models to detect analgesic properties of commonly used analgesics in healthy subjects. Methods: The battery consisted of tests eliciting electrical, mechanical and thermal (contact heat and cold pressor)-pain and included a UVB model, the thermal grill illusion and a paradigm of conditioned pain modulation. Subjects were administered fentanyl 3 μg kg-1 , phenytoin 300 mg, (S)-ketamine 10 mg and placebo (part I), or imipramine 100 mg, pregabalin 300 mg, ibuprofen 600 mg and placebo (part II). Pain measurements were performed at baseline and up to 10 h post-dose. Endpoints were analysed using a mixed model analysis of variance. Results: Sixteen subjects (8 female) completed each part. The pain tolerance threshold (PTT) for electrical stimulation was increased (all P < 0.05) compared to placebo for (S)-ketamine (+10.1%), phenytoin (+8.5%) and pregabalin (+10.8%). The PTT for mechanical pain was increased by pregabalin (+14.1%). The cold pressor PTT was increased by fentanyl (+17.1%) and pregabalin (+46.4%). Normal skin heat pain detection threshold was increased by (S)-ketamine (+3.3%), fentanyl (+2.8%) and pregabalin (+4.1%). UVB treated skin pain detection threshold was increased by fentanyl (+2.6%) and ibuprofen (+4.0%). No differences in conditioned pain modulation were observed. Conclusion: This study shows that these pain models are able to detect changes in pain thresholds after administration of different classes of analgesics in healthy subjects. The analgesic compounds all showed a unique profile in their effects on the pain tasks administered.
Striatal μ-opioid receptor availability predicts cold pressor pain threshold in healthy human subjects

Nora Hagelberg,Sargo Aalto,Lauri Tuominen,Ullamari Pesonen,Kjell Någren,Jarmo Hietala,Harry Scheinin,Antti Pertovaara,Ilkka K Martikainen

DOI: https://doi.org/10.1016/j.neulet.2012.05.042

2012-07-11

Abstract:Previous PET studies in healthy humans have shown that brain μ-opioid receptor activation during experimental pain is associated with reductions in the sensory and affective ratings of the individual pain experience. The aim of this study was to find out whether brain μ-opioid receptor binding at the resting state, in absence of painful stimulation, can be a long-term predictor of experimental pain sensitivity. We measured μ-opioid receptor binding potential (BP(ND)) with μ-opioid receptor selective radiotracer [(11)C]carfentanil and positron emission tomography (PET) in 12 healthy male subjects. Later, we recruited these subjects to participate in a separate psychophysical testing session to measure cold pressor pain threshold, cold pressor pain tolerance and tactile sensitivity with von Frey monofilaments. We used both voxel-by-voxel and region-of-interest image analyses to examine the potential associations between μ-opioid receptor BP(ND) and psychophysical measures. The results show that striatal μ-opioid receptor BP(ND) predicts cold pressor pain threshold, but not cold pressor pain tolerance or tactile sensitivity. This finding suggests that striatal μ-opioid receptor density is involved in setting individual pain threshold.
Neural Dynamics of Tonic Cold Pain: A Novel Investigation of an In-Scanner Alternative to the Cold Pressor Test in Healthy Individuals

Sonia Medina,Sam W Hughes

DOI: https://doi.org/10.1101/2024.12.03.626599

2024-12-06

Abstract:The cold pressor task (CPT) is widely used to study tonic pain during acute and chronic conditions and is often as used as a conditioning stimulus to activate descending pain control systems. However, logistical challenges in magnetic resonance imaging (MRI) limit its application, hindering the understanding of CPT's neural dynamics. To address this, we acquired resting-state functional MRI data from 30 healthy participants before, during, and after immersion in gelled-cold water, the closest in-scanner alternative to date to CPT for prolonged stimulation. Participants provided subjective pain intensity ratings after each scan, as well as average pain perceived during noxious stimulation, using a numeric rating scale (NRS). Following fMRI, participants rated their pain continuously during identical tonic noxious stimulation of the contralateral hand using a visual analogue scale (VAS). We employed three complementary methods to examine changes in brain function across fMRI conditions: a data-driven approach via independent component analysis (ICA), seed-to-whole-brain connectivity analysis with the periaqueductal grey (PAG) as seed, and spectral dynamic causal modelling (spDCM) to explore effective connectivity changes across the dorsal anterior cingulate cortex (dACC), anterior insulae (AI), thalamus, and PAG. NRS scores were significantly higher following tonic cold compared to baseline and recovery conditions. Continuous VAS reflected sustained mild-to-moderate pain over six minutes, with average VAS scores not significantly differing from NRS ratings recorded in the scanner. ICA identified engagement of descending pain control and sensorimotor networks during pain, with the latter persisting during recovery. Seed-based analysis revealed a disengagement between the PAG and cortical/subcortical regions involved in pain processing, such as the dACC, midcingulate cortex, AI, intraparietal sulcus, and precuneus. Finally, spDCM revealed tonic pain neural signature was most likely characterised by top-down inhibitory and bottom-up excitatory connections. This study establishes the cold gelled-water paradigm as a robust in-scanner alternative to CPT. By uncovering key neural dynamics of CPT, we provide new insights into the brain and brainstem mechanisms of tonic cold pain paradigms routinely used in psychophysical pain studies.

Neuroscience
Low‐dose ketamine as an adjunct to morphine: A randomized controlled trial among patients with and without current opioid use

Stine Fjendbo Galili,Bodil Hammer Bech,Hans Kirkegaard,Jette Ahrensberg,Lone Nikolajsen

DOI: https://doi.org/10.1111/acem.14983

2024-07-18

Academic Emergency Medicine

Abstract:Background Pain is a common complaint among patients presenting to the emergency department (ED), yet pain treatment is frequently suboptimal. The aim of this study was to determine the effectiveness of low‐dose ketamine (LDK) as an adjunct to morphine versus morphine alone for treatment of acute pain among ED patients with and without current opioid use. Methods Adult patients presenting with acute pain of ≥5 on a numeric rating scale (0–10) who were deemed by their treating ED physician to require intravenous opioids were randomized to receive either 0.1 mg/kg ketamine (treatment group) or isotonic saline (placebo) as an adjunct to morphine. Patients with and without current opioid use were randomized separately. Pain was measured at baseline (T0) and 10, 20, 30, 45, 60, and 120 min after randomization. The primary outcome was pain reduction from T0 to T10. Secondary outcomes included pain intensity over 120 min, need of rescue opioids, side effects, and patient and provider satisfaction. Results A total of 116 patients were included from May 2022 to August 2023. Median (IQR) age was 51 (36.5–67) years; 58% were male and 36% had current opioid use. Pain reduction from T0 to T10 was greater in the LDK group (4 [IQR 3–6]) compared to the placebo group (1 [IQR 0–2]; p = 0.001). Pain intensity was lower in the LDK group at T10, T20, and T30, compared to the placebo group. There was a higher risk of nausea, vomiting, and dissociation in the LDK group during the first 10 min. Conclusions LDK may be effective as an adjunct analgesic to morphine for short‐term pain relief in treatment of acute pain in the ED for both patients with and without current opioid use.

emergency medicine
Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans

Guido van Amerongen,Pieter S Siebenga,Rachel Gurrell,Pinky Dua,Mark Whitlock,Donal Gorman,Pieter Okkerse,Justin L Hay,Richard P Butt,Geert Jan Groeneveld

DOI: https://doi.org/10.1016/j.bja.2018.12.006

Abstract:Background: This study investigated the analgesic effects of two doses (15 and 65 mg) of PF-06372865, a novel α2/α3/α5 gamma-aminobutyric acid A (GABAA) subunit selective partial positive allosteric modulator (PAM), compared with placebo and pregabalin (300 mg) as a positive control. Methods: We performed a randomised placebo-controlled crossover study (NCT02238717) in 20 healthy subjects, using a battery of pain tasks (electrical, pressure, heat, cold and inflammatory pain, including a paradigm of conditioned pain modulation). Pharmacodynamic measurements were performed at baseline and up to 10 h after dose. Results: A dose of 15 mg PF-06372865 increased pain tolerance thresholds (PTTs) for pressure pain at a ratio of 1.11 (90% confidence interval [CI]: 1.02, 1.22) compared with placebo. A dose of 65 mg PF-06372865 led to an increase in PTT for the cold pressor at a ratio of 1.17 (90% CI: 1.03, 1.32), and pressure pain task: 1.11 (90% CI: 1.01, 1.21). Pregabalin showed an increase in PTT for pressure pain at a ratio of 1.15 (95% CI: 1.06, 1.26) and cold pressor task: 1.31 (90% CI: 1.16, 1.48). Conclusion: We conclude that PF-06372865 has analgesic potential at doses that do not induce significant sedation or other intolerable adverse events limiting its clinical use. In addition, the present study established the potential role for this battery of pain tasks as a tool in the development of analgesics with a novel mechanism of action, for the treatment of various pain states including neuropathic pain and to establish proof-of-concept. Clinical trials registration: NCT0223871.
Characterizing the opioidergic mechanisms of repetitive transcranial magnetic stimulation–induced analgesia: a randomized controlled trial

Ying Liu,Junfeng Sun,Chaomin Wu,Jinxuan Ren,Yanni He,Na Sun,Hao Huang,QunShan Chen,Dan Liu,Yangyuxin Huang,Feng Xu,Lina Yu,Bernadette M Fitzgibbon,Robin F H Cash,Paul B Fitzgerald,Min Yan,Xianwei Che,Bernadette M. Fitzgibbon,Robin F. H. Cash,Paul B. Fitzgerald

DOI: https://doi.org/10.1097/j.pain.0000000000003220

IF: 7.926

2024-03-26

Pain

Abstract:Abstract Repetitive transcranial magnetic stimulation (rTMS) is a promising technology to reduce chronic pain. Investigating the mechanisms of rTMS analgesia holds the potential to improve treatment efficacy. Using a double-blind and placebo-controlled design at both stimulation and pharmacologic ends, this study investigated the opioidergic mechanisms of rTMS analgesia by abolishing and recovering analgesia in 2 separate stages across brain regions and TMS doses. A group of 45 healthy participants were equally randomized to the primary motor cortex (M1), the dorsolateral prefrontal cortex (DLPFC), and the Sham group. In each session, participants received an intravenous infusion of naloxone or saline before the first rTMS session. Participants then received a second dose of rTMS session after the drugs were metabolized at 90 minutes. M1-rTMS–induced analgesia was abolished by naloxone compared with saline and was recovered by the second rTMS run when naloxone was metabolized. In the DLPFC, double but not the first TMS session induced significant pain reduction in the saline condition, resulting in less pain compared with the naloxone condition. In addition, TMS over the M1 or DLPFC selectively increased plasma concentrations of β-endorphin or encephalin, respectively. Overall, we present causal evidence that opioidergic mechanisms are involved in both M1-induced and DLPFC-rTMS–induced analgesia; however, these are shaped by rTMS dosage and the release of different endogenous opioids.

neurosciences,clinical neurology,anesthesiology
Effect of Intrathecal Dexmedetomidine on Spinal Morphine Analgesia in Patients with Refractory Cancer Pain

Hong-Jun Liu,Xian-Zhong Gao,Xiao-Ming Liu,Ming Xia,Wei-Yan Li,Yi Jin

DOI: https://doi.org/10.1089/jpm.2013.0544

2014-01-01

Journal of Palliative Medicine

Abstract:Background: Systemic administration of dexmedetomidine has been shown to reduce opioid consumption and improve analgesia satisfaction. The purpose of this study was to investigate the effect of intrathecal dexmedetomidine on spinal morphine analgesia in patients with refractory cancer pain. Methods: A double-blinded crossover study was designed and performed. Patients were randomly allocated in one of the two phases. Phase M received intrathecal morphine administration. Phase M+D received intrathecal morphine plus dexmedetomidine administration. All patients were monitored for 7 days and crossed over to alternate phase for another 1-week observation. Daily average visual analog scale (VAS) pain score, pain frequency, sleep deprivation, daily morphine consumption, bolus dose injection times, and side effects were all recorded. Results: Pain intensity and frequency were significantly decreased in both phases compared with baseline. Daily morphine consumption and bolus dose injection times during phase M+D were significantly decreased compared with phase M. The incidences of constipation were significantly reduced in both phases compared with baseline administration, but nausea and vomiting were significantly increased. No serious side effects such as respiratory inhibition were observed in this study. Conclusions: Intrathecal administration of dexmedetomidine and morphine reduced the morphine consumption in patients with refractory cancer pain. There were no serious side effects.
Effectiveness and Safety of Intrathecal Morphine for Percutaneous Endoscopic Lumbar Discectomy under Low-Dose Ropivacaine: a Prospective, Randomized, Double-Blind Clinical Trial

Lei Yue,Feng Zhang,Guanzhang Mu,Meixia Shang,Zengmao Lin,Haolin Sun

DOI: https://doi.org/10.1016/j.spinee.2023.03.001

2023-01-01

Abstract:BACKGROUND CONTEXT:Percutaneous endoscopic lumbar discectomy (PELD) is a surgical setting that requires minimal motor impairment. Low-dose spinal ropivacaine induces little motor blockade and could be ideal for maintaining safety of PELD, but its analgesic efficacy is questionable. An adjunct analgesic approach is needed to maximize the benefits of low-dose spinal ropivacaine for PELD.PURPOSE:This study aimed to explore the effectiveness and safety of 100 µg intrathecal morphine (ITM) as an adjuvant analgesic method for PELD under low-dose spinal ropivacaine.STUDY DESIGN:A double-blind, randomized, placebo-controlled trial.TRIAL REGISTRATION:ChiCTR2000039842 (www.chictr.org.cn).SAMPLE:Ninety patients scheduled for elective single-level PELD under low-dose spinal ropivacaine.OUTCOME MEASURES:The primary outcome was the overall intraoperative visual analogue scale (VAS) score for pain. Secondary outcomes were intraoperative VAS scores assessed at multiple timepoints; intraoperative rescue analgesic requirement; postoperative VAS scores; disability scale; patients' satisfaction with anesthesia; adverse events; and radiographic outcomes.METHODS:Patients were randomized to receive low-dose ropivacaine spinal anesthesia with (ITM group, n=45) or without (control group, n=45) 100 µg ITM.RESULTS:The overall intraoperative VAS score in the ITM group was significantly lower than that in the control group (0 [0, 1] vs 2 [1, 3], p<.001). During operation, the VAS scores at cannula insertion, 30 minutes after insertion, 60 minutes after insertion, and 120 minutes after insertion were all significantly lower in the ITM group (all p<.05). Less patients in the ITM group required rescue analgesia during operation compared with those in the control group (14% vs 42%, p= .003). The VAS score for back pain in the ITM group was lower than that in the control group at 1 hour, 12 hours, and 24 hours postoperatively. Besides, the satisfaction score in the ITM group was significantly higher than that in the control group (p=.017). For adverse events, 8/43 of ITM and 1/44 of control participants experienced pruritus (p=.014), with a relative risk (95% confidence interval) of 8.37 (1.09-64.16). The incidence of other adverse events was similar between the two groups. Of note, respiratory depression occurred in one ITM-treated patient.CONCLUSION:The addition of 100 µg ITM to low-dose ropivacaine appears to be effective in analgesia without compromised motor function for PELD; however, ITM increased the risk of pruritus and clinicians should be vigilant about its potential risk of respiratory depression.
Effectiveness and safety of prehospital analgesia with nalbuphine and paracetamol versus morphine by paramedics - an observational study

Marvin Deslandes,Martin Deicke,Julia Johanna Grannemann,Jochen Hinkelbein,Annika Hoyer,Matthias Kalmbach,André Kobiella,Bernd Strickmann,Thomas Plappert,Gerrit Jansen

DOI: https://doi.org/10.1186/s13049-024-01215-z

2024-05-12

Scandinavian Journal of Trauma Resuscitation and Emergency Medicine

Abstract:Despite the development of various analgesic concepts, prehospital oligoanalgesia remains very common. The present work examines prehospital analgesia by paramedics using morphine vs. nalbuphine + paracetamol.

emergency medicine
Low-dose ketamine infusion to facilitate opioid tapering in chronic non-cancer pain with opioid-use disorder: a historical cohort study

Antoine Elyn,Anne Roussin,Cécile Lestrade,Nicolas Franchitto,Bénédicte Jullian,Nathalie Cantagrel

DOI: https://doi.org/10.1136/rapm-2023-105035

2024-03-18

Regional Anesthesia & Pain Medicine

Abstract:Background Long-term opioid use is associated with pharmacological tolerance, a risk of misuse and hyperalgesia in patients with chronic pain (CP). Tapering is challenging in this context, particularly with comorbid opioid-use disorder (OUD). The antihyperalgesic effect of ketamine, through N-methyl-D-aspartate (NMDA) antagonism, could be useful. We aimed to describe the changes in the dose of opioids consumed over 1 year after a 5-day hospitalisation with ketamine infusion for CP patients with OUD. Methods We performed a historical cohort study using a medical chart from 1 January 2014 to 31 December 2019. Patients were long-term opioid users with OUD and CP, followed by the Pain Center of the University Hospital of Toulouse, for which outpatient progressive tapering failed. Ketamine was administered at a low dose to initiate tapering during a 5-day hospitalisation. Results 59 patients were included, with 64% of them female and a mean age of 48±10 years old. The most frequent CP aetiologies were back pain (53%) and fibromyalgia (17%). The baseline opioid daily dose was 207 mg (±128) morphine milligram equivalent (MME). It was lowered to 92±72 mg MME at discharge (p<0.001), 99±77 mg at 3 months (p<0.001) and 103±106 mg at 12 months. More than 50% tapering was achieved immediately for 40 patients (68%), with immediate cessation for seven patients (12%). 17 patients were lost to follow-up. Conclusions A 5-day hospitalisation with a low-dose ketamine infusion appeared useful to facilitate opioid tapering in long-term opioid users with CP and OUD. Ketamine was well tolerated, and patients did not present significant withdrawal symptoms. Prospective and comparative studies are needed to confirm our findings.

anesthesiology
Dexmedetomidine Attenuates Persistent Postsurgical Pain by Upregulating K+–Cl− Cotransporter-2 in the Spinal Dorsal Horn in Rats

Shuhong Dai,Yu Qi,Jie Fu,Na Li,Xu Zhang,Juan Zhang,Wei Zhang,Haijun Xu,Hai Zhou,Zhengliang Ma

DOI: https://doi.org/10.2147/jpr.s158737

IF: 2.8319

2018-01-01

Journal of Pain Research

Abstract:Background: Dexmedetomidine (DEX) could have an analgesic effect on pain transmission through the modulation of brain-derived neurotrophic factor (BDNF). In addition, KCC2-induced shift in neuronal Cl-homeostasis is crucial for postsynaptic inhibition mediated by GABAA receptors. Accumulating evidence shows that nerve injury, peripheral inflammation and stress activate the spinal BDNF/TrkB signal, which results in the downregulation of KCC2 transport and expression, eventually leads to GAGAergic disinhibition and hyperalgesia. The aim of this experiment was to explore the interaction between DEX and KCC2 at a molecular level in rats in the persistent postsurgical pain (PPSP). Methods: PPSP in rats was evoked by the skin/muscle incision and retraction (SMIR). Mechanical hypersensitivity was assessed with the Dynamic Plantar Aesthesiometer. Western blot and immunofluorescence assay were used to assess the expressions of related proteins. Results: In the first part of our experiment, the results revealed that the BDNF/TrkB-KCC2 signal plays a critical role in the development of SMIR-evoked PPSP; the second part showed that intraperitoneal administrations of 40 mu g/kg DEX at 15 min presurgery and 1 to 3 days post-surgery significantly attenuated SMIR-evoked PPSP. Simultaneously, SMIR-induced KCC2 downregulation was partly reversed, which coincided with the inhibition of the BDNF/ TrkB signal in the spinal dorsal horn. Moreover, intrathecal administrations of KCC2 inhibitor VU0240551 significantly reduced the analgesic effect of DEX on SMIR-evoked PPSP. Conclusion: The results of our study indicated that DEX attenuated PPSP by restoring KCC2 function through reducing BDNF/TrkB signal in the spinal dorsal horn in rats, which provides a new insight into the treatment of chronic pain in clinical postsurgical pain management.
Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination

Katja Linher-Melville,Yong Fang Zhu,Jesse Sidhu,Natalka Parzei,Ayesha Shahid,Gireesh Seesankar,Danny Ma,Zhi Wang,Natalie Zacal,Manu Sharma,Vikas Parihar,Ramesh Zacharias,Gurmit Singh

DOI: https://doi.org/10.1371/journal.pone.0234176

IF: 3.7

2020-06-04

PLoS ONE

Abstract:Chronic neuropathic pain (NP) is a growing clinical problem for which effective treatments, aside from non-steroidal anti-inflammatory drugs and opioids, are lacking. Cannabinoids are emerging as potentially promising agents to manage neuroimmune effects associated with nociception. In particular, Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their combination are being considered as therapeutic alternatives for treatment of NP. This study aimed to examine whether sex affects long-term outcomes on persistent mechanical hypersensitivity 7 weeks after ceasing cannabinoid administration. Clinically relevant low doses of THC, CBD, and a 1:1 combination of THC:CBD extracts, in medium chain triglyceride (MCT) oil, were orally gavaged for 14 consecutive days to age-matched groups of male and female sexually mature Sprague Dawley rats. Treatments commenced one day after surgically inducing a pro-nociceptive state using a peripheral sciatic nerve cuff. The analgesic efficacy of each phytocannabinoid was assessed relative to MCT oil using hind paw mechanical behavioural testing once a week for 9 weeks. In vivo intracellular electrophysiology was recorded at endpoint to characterize soma threshold changes in primary afferent sensory neurons within dorsal root ganglia (DRG) innervated by the affected sciatic nerve. The thymus, spleen, and DRG were collected post-sacrifice and analyzed for long-term effects on markers associated with T lymphocytes at the RNA level using qPCR. Administration of cannabinoids, particularly the 1:1 combination of THC, elicited a sustained mechanical anti-hypersensitive effect in males with persistent peripheral NP, which corresponded to beneficial changes in myelinated Aβ mechanoreceptive fibers. Specific immune cell markers associated with T cell differentiation and pro-inflammatory cytokines, previously implicated in repair processes, were differentially up-regulated by cannabinoids in males treated with cannabinoids, but not in females, warranting further investigation into sexual dimorphisms that may underlie treatment outcomes.
Morphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effects

Laura S Stone,Jonathan P German,Kelly F Kitto,Carolyn A Fairbanks,George L Wilcox

DOI: https://doi.org/10.1371/journal.pone.0109903

IF: 3.7

2014-10-09

PLoS ONE

Abstract:Opioids are used to manage all types of pain including acute, cancer, chronic neuropathic and inflammatory pain. Unfortunately, opioid-related adverse effects such as respiratory depression, tolerance, physical dependence and addiction have led to an underutilization of these compounds for adequate pain relief. One strategy to improve the therapeutic utility of opioids is to co-administer them with other analgesic agents such as agonists acting at α2-adrenergic receptors (α2ARs). Analgesics acting at α2ARs and opioid receptors (ORs) frequently synergize when co-administered in vivo. Multimodal analgesic techniques offer advantages over single drug treatments as synergistic combination therapies produce analgesia at lower doses, thus reducing undesired side effects. This inference presumes, however, that the synergistic interaction is limited to the analgesic effects. In order to test this hypothesis, we examined the effects of α2AR/OR combination therapy in acute antinociception and in the often-undesired side effects of sedation and cardiovascular depression in awake unrestrained mice. Morphine, clonidine or their combination was administered by spinal or systemic injection in awake mice. Antinociception was determined using the warm water tail flick assay (52.5°C). Sedation/motor impairment was evaluated using the accelerating rotarod assay and cardiovascular function was monitored by pulse oximetry. Data were converted to percent maximum possible effect and isobolographic analysis was performed to determine if an interaction was subadditive, additive or synergistic. Synergistic interactions between morphine and clonidine were observed in the antinociceptive but not in the sedative/motor or cardiovascular effects. As a result, the therapeutic window was improved ∼200-fold and antinociception was achieved at non-sedating doses with little to no cardiovascular depression. In addition, combination therapy resulted in greater maximum analgesic efficacy over either drug alone. These data support the utility of combination adrenergic/opioid therapy in pain management for antinociceptive efficacy with reduced side-effect liability.
Randomized and Double -Blind Controlled Clinical Trial of Dezocine Injection for Analgesia

SUN Li,XU Guo-zhu,SHEN Li-yang,DENG Yan-ping,ZHU Tian-yue,XIE Qi-wei,WANG Jie-jun,XIE Guang-ru,SHI Jie

DOI: https://doi.org/10.13699/j.cnki.1001-6821.2014.04.012

2014-01-01

Abstract:Objective To evaluate the efficacy and safety of dezocine injection for analgesia.Methods A multicenter , randomized , double blind, parallel group controlled study was performed with dezocine as the test drug , and pethidine injection and morphine injection as positive con-trol for the single treatment and 7 days treatment of moderate and severe pain , respectively.The test drug was dezocine injection.One hundred of forty patients with postoperative moderate and severe pain received single treatment with dezocine ( single injection of dezocine , n=70 ) or pethi-dine ( single injection of pethidine and placebo , n =70 ).Fifty -six cancer pain patients received 7 days treatment with dezocine or morphine as follows:the test group was intramuscularly injected two dezocines each time ( n=31 ) , and the control group was injected morphine and moe-phine simulation respectively ( n=25 , four times a day ) .Pain intensity difference ( PID) was evaluated as the primary analgesic effect criteria.Results There was no significant difference in PID between the test group and the control one both in the controlled trail of postoperative pain and that of chronic cancer pain.The most common adverse reactions of dezocine were nausea , vomiting and dizziness , et al.Conclusion The analgesic effect and adverse effects of dezocine were similar to those of morphine , which indicats dezocine is an effective and safe analgesic for postoperative pain and chronic cancer pain that are moderate and severe.
Antinociceptive Effect of Spirocyclopiperazinium Salt Compound DXL-A-24 and the Underlying Mechanism

Ding Wang,Hua Yang,Yingying Liang,Xin Wang,Xiaolei Du,Runtao Li,Yimin Jiang,Jia Ye

DOI: https://doi.org/10.1007/s11064-019-02899-x

IF: 4.4

2019-01-01

Neurochemical Research

Abstract:The antinociceptive effects of spirocyclopiperazinium salt compound DXL-A-24 on neuropathic pain and chemical-stimulated pain were investigated in this study. After the administration of DXL-A-24, the paw withdrawal latency (PWL) and mechanical withdrawal threshold (MWT) were increased in rats suffering from neuropathic pain (chronic constriction injury, CCI) on days 1, 3, 5, 7 and 14 after surgery, and pain responses were inhibited in mice stimulated with chemicals (formalin or acetic acid). In the analysis of antinociceptive targets, the effect of DXL-A-24 was blocked by a peripheral nicotinic acetylcholine receptor (nAChR) antagonist (hexamethonium, Hex) or α7 nAChR antagonist (methyllycaconitine, MLA) in the formalin test. Meanwhile, the effect of DXL-A-24 was also blocked by a peripheral muscarinic acetylcholine receptor (mAChR) antagonist (atropine methylnitrate, Amn) or M4 mAChR antagonist (tropicamide, TRO). The antinociceptive signalling pathway was explored using molecular biology methods in ipsilateral dorsal root ganglions (DRGs) of CCI rats after the administration of DXL-A-24 for 7 days. Western blot analyses showed that the increased levels of phosphorylation of calcium/calmodulin-dependent protein kinase II alpha (CaMKIIα) and cAMP response element-binding protein (CREB) were eliminated, and the qRT-PCR assay showed that the increase in the expression of Tumor necrosis factor alpha (TNF-α) mRNA was reduced. Meanwhile, immunofluorescence staining revealed that the increase in calcitonin gene related peptide (CGRP) expression was inhibited by the administration of DXL-A-24, and the effect was blocked by MLA or TRO. In conclusion, DXL-A-24 exerts significant antinociceptive effects on neuropathic pain and chemical-stimulated pain. The antinociceptive effect of DXL-A-24 is probably attributed to the activation of peripheral α7 nAChR and M4 mAChR, the subsequent inhibition of the CaMKIIα/CREB signalling pathway, and finally the inhibition of TNF-α and CGRP expression.

Sequential extraction of wheat seed proteins.

Randomized and Double-Blind Controlled Clinical Trial of Tilidine Hydrochloride Oral Solution for Analgesia

Maternal diabetes mellitus is associated with altered deposition of fibrin-type fibrinoid at the villous surface in term placentae.

A novel opioid/pramipexole combination treatment for the management of acute pain: a pilot study

Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial

Assessment of suicidal behavior in the emergency department.

The use of a battery of pain models to detect analgesic properties of compounds: a two-part four-way crossover study

Striatal μ-opioid receptor availability predicts cold pressor pain threshold in healthy human subjects

Neural Dynamics of Tonic Cold Pain: A Novel Investigation of an In-Scanner Alternative to the Cold Pressor Test in Healthy Individuals

Low‐dose ketamine as an adjunct to morphine: A randomized controlled trial among patients with and without current opioid use

Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans

Characterizing the opioidergic mechanisms of repetitive transcranial magnetic stimulation–induced analgesia: a randomized controlled trial

Effect of Intrathecal Dexmedetomidine on Spinal Morphine Analgesia in Patients with Refractory Cancer Pain

Effectiveness and Safety of Intrathecal Morphine for Percutaneous Endoscopic Lumbar Discectomy under Low-Dose Ropivacaine: a Prospective, Randomized, Double-Blind Clinical Trial

Effectiveness and safety of prehospital analgesia with nalbuphine and paracetamol versus morphine by paramedics - an observational study

Low-dose ketamine infusion to facilitate opioid tapering in chronic non-cancer pain with opioid-use disorder: a historical cohort study

Dexmedetomidine Attenuates Persistent Postsurgical Pain by Upregulating K+–Cl− Cotransporter-2 in the Spinal Dorsal Horn in Rats

Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination

Morphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effects

Randomized and Double -Blind Controlled Clinical Trial of Dezocine Injection for Analgesia

Antinociceptive Effect of Spirocyclopiperazinium Salt Compound DXL-A-24 and the Underlying Mechanism